Single-dose psilocybin and rumination in people with depression
About this title
Read the official source — NCT06247839Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
What will I do during this study?
You receive a single 25 mg dose of psilocybin in an open-label fMRI study. The team measures rumination and brain activity around dosing, then follows selected outcomes at 3, 6, 9 and 12 weeks.
- Listed locations
- CharlestownSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 20
- Sponsor
- Sharmin Ghaznavi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT06247839
- Official title
Show the full official title
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Recruitment & locations
Charlestown
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sharmin Ghaznavi.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
